Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR-IIR-17012529Phase 3Recruiting
Phase 3, randomised, open-label trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Started Sep 2017; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR-IIR-17012529.